Nov and uPAR as non-invasive biomarkers for the prediction of laryngeal squamous cell carcinoma

Nov and uPAR as non-invasive biomarkers for the prediction of laryngeal squamous cell carcinoma - BEAL

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00033427

Enrollment

140

Registered

2024-04-04

Start date

2022-02-01

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

C32

Interventions

Group 1: newly diagnosed malignant laryngeal carcinoma Group 2: Vocal fold polyp or leukoplakia as a benign laryngeal lesion Group 3: Septorhinoplasty patients without concomitant diseases (control)

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: - Written declaration of consent - Histologically confirmed diagnosis of squamous cell carcinoma of the larynx, vocal fold leukoplakia or vocal fold polyps

Exclusion criteria

Exclusion criteria: - no written consent - not of legal age - Laryngeal diseases other than those mentioned in the inclusion criteria - Malignant tumors in the last 5 years

Design outcomes

Primary

Measure	Time frame
The aim is to investigate the efficacy of the Nov and uPAR biomarkers for the early detection of laryngeal carcinoma	—

Secondary

Measure	Time frame
Effectiveness of the markers for discriminating between malignant and benign laryngeal lesions and as progression parameters	—

Countries

Germany

Contacts

Public ContactSarina Müller

Hals-Nasen-Ohren-Klinik – Kopf- und Halschirurgie des Uniklinikums Erlangen

sarina.mueller(at)uk-erlangen.de+49 9131 85-33156

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026